FibroGen, Inc. (NASDAQ:FGEN) Short Interest Down 6.1% in March

FibroGen, Inc. (NASDAQ:FGEN - Get Free Report) was the target of a large drop in short interest during the month of March. As of March 31st, there was short interest totalling 5,190,000 shares, a drop of 6.1% from the March 15th total of 5,530,000 shares. Currently, 5.7% of the company's stock are short sold. Based on an average daily volume of 2,740,000 shares, the short-interest ratio is presently 1.9 days.

FibroGen Stock Performance

Shares of FGEN stock traded down $0.01 on Tuesday, reaching $1.30. The stock had a trading volume of 863,694 shares, compared to its average volume of 2,561,018. The stock has a market cap of $128.40 million, a P/E ratio of -0.44 and a beta of 0.70. FibroGen has a 1 year low of $0.33 and a 1 year high of $20.90. The company has a 50 day simple moving average of $2.00 and a 200 day simple moving average of $1.19.

FibroGen (NASDAQ:FGEN - Get Free Report) last announced its earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.15). The company had revenue of $27.14 million during the quarter, compared to the consensus estimate of $40.00 million. On average, equities research analysts anticipate that FibroGen will post -1.09 earnings per share for the current fiscal year.

Insider Buying and Selling at FibroGen

In other FibroGen news, CEO Thane Wettig bought 50,000 shares of the business's stock in a transaction on Thursday, March 7th. The shares were acquired at an average cost of $1.91 per share, for a total transaction of $95,500.00. Following the purchase, the chief executive officer now owns 470,178 shares in the company, valued at approximately $898,039.98. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 2.39% of the company's stock.

Hedge Funds Weigh In On FibroGen

A number of institutional investors have recently bought and sold shares of FGEN. Armistice Capital LLC raised its holdings in FibroGen by 81.2% in the 3rd quarter. Armistice Capital LLC now owns 7,892,000 shares of the biopharmaceutical company's stock worth $6,810,000 after purchasing an additional 3,536,000 shares during the period. Acadian Asset Management LLC bought a new stake in FibroGen during the third quarter valued at about $1,391,000. Jacobs Levy Equity Management Inc. raised its holdings in FibroGen by 156.4% during the third quarter. Jacobs Levy Equity Management Inc. now owns 2,557,128 shares of the biopharmaceutical company's stock valued at $2,207,000 after acquiring an additional 1,559,903 shares during the period. Federated Hermes Inc. raised its holdings in FibroGen by 84.1% during the first quarter. Federated Hermes Inc. now owns 2,395,883 shares of the biopharmaceutical company's stock valued at $28,799,000 after acquiring an additional 1,094,403 shares during the period. Finally, Primecap Management Co. CA raised its holdings in FibroGen by 7.7% during the third quarter. Primecap Management Co. CA now owns 14,724,968 shares of the biopharmaceutical company's stock valued at $12,706,000 after acquiring an additional 1,047,380 shares during the period. 72.71% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, William Blair restated a "market perform" rating on shares of FibroGen in a research note on Tuesday, February 27th. One investment analyst has rated the stock with a sell rating and four have assigned a hold rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $17.00.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.